X4 Pharmaceuticals (XFOR) Gross Profit (2024 - 2026)

X4 Pharmaceuticals (XFOR) has reported Gross Profit for 3 consecutive years, with $7.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Gross Profit rose 336.49% year-over-year to $7.2 million; the trailing twelve-month figure through Jun 2026 stood at $12.9 million (down 52.52% YoY), and the FY2025 full-year result was $29.4 million, up 1567.95% from the prior year.
• Gross Profit rose to $7.2 million in Q2 2026 per XFOR's latest filing, from $2.1 million in the prior quarter.
• Across five years, Gross Profit topped out at $24.1 million in Q1 2025 and bottomed at $295000.0 in Q2 2024.
• Historically, Gross Profit has averaged $4.5 million across 3 years, with a median of $1.6 million in 2025.
• The sharpest annual moves came in 2025 and 2026: Gross Profit surged 458.31% in 2025, then sank 91.24% in 2026.
• Over 3 years, Gross Profit stood at $1.1 million in 2024, then soared by 94.7% to $2.2 million in 2025, then jumped by 226.18% to $7.2 million in 2026.
• According to Business Quant data, Gross Profit over the past three periods registered $7.2 million, $2.1 million, and $2.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.